Koele, S.E., Stoycheva, K., Mtweve, C., Manyama, C., Mpagama, S., Mhimbira, F., Wallis, R., Ntinginya, N.E., Liyoyo, A., Huglin, B. and Minja, L.T., 2025. Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. Journal of Antimicrobial Chemotherapy, p.dkaf210.

Minja, L.T., van der Feltz, I., Manyama, C., Mpagama, S., Mhimbira, F., Noreña, I., Sebe, M., Rassool, M., Wallis, R., Ntinginya, N.E. and Liyoyo, A., A Prospective, Randomised, Open Label Phase 2b Dose-Finding​ Trial of Delpazolid in Combination with Bedaquiline, Delamanid and Moxifloxacin for Pulmonary Tuberculosis: DECODE.

Weld, E.D., Beattie, T., Moodley, J., Mapendere, M., Salles, I., Solans, B.P., Nonyane, B.A., Wiesner, L., Nielson, T., Edward, V.A. and Chihota, V., 2025. Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial. The Lancet HIV.

Garrett, N., Tapley, A., Hudson, A., Dadabhai, S., Zhang, B., Mgodi, N.M., Andriesen, J., Takalani, A., Fisher, L.H., Kee, J.J. and Magaret, C.A., 2025. Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study. EClinicalMedicine, 80.